ClinTrial Research Teams Up With Trially AI to Multiply Enrollment in Complex Clinical Trials
"Trially's proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools."
Share
How Native AI Technology is Advancing Site Operations
By implementing Trially's AI EMR matching technology, CTR has experienced notable improvements in its clinical trial operations:
Increased monthly patient enrollment rates
Significant reduction in screen failures
Less time spent on manual EHR chart reviews
Increased site revenue due to higher study KPIs
Enhanced diversity through real-time protocol population analytics
Instant API integrations with multiple EHR systems including IMS, TriMed, Athena, RelyMed, and others
Expanded site network capabilities, with successful implementations across multiple therapy areas including Behavioral Health and CNS, Respiratory, Internal Medicine Gastrointestinal, Nephrology and Ophthalmology
"Our mission at CTR is to build the premier, next-generation site management organization, setting new standards of excellence in clinical trial management," said ClinTrial Research's Chief Commercial Officer, Sam Searcy. "Our partnership with Trially aligns perfectly with our commitment to using AI-driven data analytics and high-precision patient identification to accelerate clinical trial timelines. Trially's proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools."
Setting New Standards for AI Clinical Trial Enrollment
The partnership demonstrates CTR's commitment to setting new standards of excellence in clinical trial management and represents a significant step forward in Trially's mission to get life-saving therapies to patients faster. Both organizations share a vision of accelerating the development of new treatments through more efficient, transparent, and inclusive clinical trials.
"We built Trially to solve the root causes of clinical trial delays," said Trially CEO Kyle McAllister. "The team at CTR has done an amazing job integrating our technology into their workflow. Their network of clinical partners really knows how to put our platform to work, making it their top source for finding qualified patients. What impresses me most is how CTR balances technological efficiency with their unwavering commitment to patient care and data security. It's been rewarding to see how they've adapted our solution across different systems to accelerate their enrollment timelines."
For more information about the partnership, visit trially.ai.
About Trially
Trially® is shaping the future of clinical trial recruitment with its proprietary AI matching technology that safely unlocks rich clinical data to enroll qualified patients faster. Proven to multiply enrollment rates by 200%, reduce screen failures by 73%, and improve site efficiency by 90%, Trially's site-based software rapidly integrates with any EMR or CRM while maintaining full compliance with HIPAA, SOC 2, FDA 21 CFR Part 11 and ISO 27001 regulations. Designed to meet the needs of Physicians, Research Sites, Sponsors and CROs, Trially empowers you to achieve outstanding results in clinical research. For more information visit trially.ai.
About ClinTrial Research
ClinTrial Research (CTR) is a next-generation SMO deploying innovative technology, driving positive physician and patient-centered clinical excellence, while providing high-quality data analytics to Sponsors and CRO partners. CTR is Empowering Research, Enhancing Lives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Applied StemCell Appoints Dolores Baksh, Ph.D., as Chief Executive Officer
Dolores Baksh, Ph.D. MILPITAS, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Applied StemCell, a genome engineering product and services company, announced today the appointment of Dolores Baksh, Ph.D., as Chief Executive Officer. Company founder and former CEO Ruby Tsai, Ph.D., will continue to guide scientific strategy, innovation, and strategic collaborations as President and Chief Scientific Officer (CSO). 'Dolores brings exactly the kind of leadership we need to help scale Applied StemCell,' said Dr. Tsai. 'Her deep experience in commercializing advanced therapies, combined with her ability to execute high growth-oriented strategies, makes her an ideal partner for our next phase of growth. I am excited to focus on the tremendous opportunity to advance Applied StemCell's proprietary genome engineering platforms to help accelerate the adoption of cell and gene therapies.' Dr. Baksh joins Applied StemCell with more than 20 years of leadership in the life sciences industry, including prior roles as founding CEO of Hyperius Biotech and CEO of TAAV Biomanufacturing Solutions. She has helped build and scale companies at the forefront of cell and gene therapy manufacturing, with a focus on enabling technologies that improve quality, reduce cost, and accelerate access for patients. 'I'm thrilled to join Applied StemCell at such a pivotal time,' said Dr. Baksh. 'Ruby and the team have built a remarkable foundation of innovation, and I look forward to helping amplify that legacy by expanding our commercial reach, accelerating new product development, and forging partnerships that translate scientific breakthroughs into real-world impact.' Applied StemCell is known for its proprietary TARGATT™ large knock-in technology, custom iPSC services, and GMP-compliant cell lines that support both research and therapeutic development. With Dr. Baksh's appointment, the company is poised to strengthen its position as a trusted partner to biopharma companies advancing next-generation therapies. About Applied StemCellFounded in 2008 to provide industry and academic researchers with the ability to leverage the power of gene editing and induced pluripotent stem cells (iPSC), Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. With a focus on genome engineering products and services, our patented technologies ensure a clear IP path to commercialization. For media inquiries, please contact:Pia Abola, of MarketingApplied 457-1312 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
4 hours ago
- Time Business News
Top Benefits of Implementing AI in Medical Billing Systems
In the healthcare sector, the incorporation of AI, especially in medical billing systems, has brought a radical change. The use of AI in billing has the potential to save hospitals and medical centers from a huge amount of administrative costs, as it can also lower the risk of human errors and speed up the process of claims. In today's competitive healthcare market, AI medical billing software is no longer optional but essential for survival. This article explores the top benefits of implementing AI in medical billing systems and how it reshapes revenue cycle management. AI algorithms eliminate human errors in calculations and coding mistakes that frequently occur in manual billing processes. Machine learning systems are always learning past data patterns to identify the risk of billing discrepancies and stop them from being submitted. Accurate billing enhances revenue consistency and operational efficiency. AI medical billing systems process insurance claims in real-time, reducing the time of the claiming process and verification. Automated systems check eligibility within seconds. Instant verification of patient insurance coverage and benefits accelerates the entire billing cycle significantly. Advanced medical billing software minimizes manual tasks, allowing the medical facilities to allocate these human resources to patient care. AI in medical billing systems can significantly cut administrative costs by 40% through reducing paper usage, postage, and other administrative overhead expenses. Makes the staff available for other activities related to patient care and has a higher value. AI adjusts billing codes and procedures autonomously to accommodate the various healthcare regulations that change frequently, for example, HIPAA and ICD-10. Such extensive documentation and audit trails would allow one to be ready for any regulatory inspection and consent without manual preparation. Automated monitoring of coding accuracy helps maintain adherence to industry standards and reduces compliance violations. AI-powered systems enable healthcare providers to see the trends in billing that are useful for future planning. Every day, access to the claims, denials, and revenue trends is made possible through the use of dashboards. Data-driven insights allow providers to optimize financial strategies proactively. AI in medical billing software creates transparent financial tracking systems that provide real-time visibility into revenue streams and outstanding balances. Predictive analytics identify potential payment delays and collection issues before they impact cash flow stability. Improves financial planning and stability for healthcare providers. AI-powered systems send personalized payment reminders based on patient preferences and payment history patterns. Intelligent scheduling of follow-up communications maximizes collection rates while maintaining positive patient relationships Automated payment plan suggestions and flexible options reduce patient financial stress. AI will enhance fraud detection in medical billing by identifying unusual patterns and flagging potentially fraudulent activities far more efficiently than traditional methods. Machine learning algorithms will analyze billing data continuously to identify potential fraud, including overbilling or upcoding. AI systems will send instant alerts to billing departments for immediate investigation and action. When patients are provided with transparent billing processes and accurate cost estimates, they are more inclined to trust the healthcare providers, and consequently, their trust levels increase. Moreover, AI chatbots integrated into user-friendly patient portals not only deliver quick billing answers but also offer payment options. By offering various communication methods, patients can receive their bill information through the channel they prefer (text, email, or call) and thus always be informed. Machine learning algorithms will enhance her performance by going through successful billing patterns and identifying new areas of optimization. The systems can update themselves, adjust to changes in rules, different coding, and new practices of the industry without the need for manual setup. Artificial intelligence-powered continuous process improvement ensures that healthcare software innovation in medical billing systems is in line with the changes in healthcare requirements. The adoption of AI in medical billing systems is transforming healthcare operations by reducing errors, ensuring compliance, and improving both financial stability and patient satisfaction. From faster claims processing to predictive analytics, AI empowers healthcare providers to manage revenue cycles more the industry continues to embrace digital transformation, investing in medical billing software is essential to optimize operations, achieve sustainable growth, and stay competitive in the evolving future of healthcare. TIME BUSINESS NEWS
Business Wire
4 hours ago
- Business Wire
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™
LAVAL, Québec--(BUSINESS WIRE)-- Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. ('Steel'), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. 'We're proud to be supporting Steel Therapeutics at this key stage of their development journey,' said Steve Mason, Co-COO at Altasciences. 'Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.' Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach broader patient populations under FDA oversight. Steel engaged Altasciences due to their deep expertise in preclinical safety evaluation and proven ability to execute with speed and precision. 'Working with Altasciences allows us to maintain the highest standards of quality as we move Fizurex™ into its next phase of development,' said Matt Stahl, CEO and Founder of Steel Therapeutics. 'This study represents a major step forward for our company and for the patients who stand to benefit from more consistent, scalable access to this treatment.' Altasciences' integrated, collaborative approach to drug development enables companies like Steel to move efficiently from discovery through to clinical trials, all under one organizational umbrella. 'We look forward to continuing our partnership with Steel Therapeutics as they advance their portfolio of innovative, patient-focused therapies,' added Mason. About Altasciences Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Steel Therapeutics' mission is to improve the lives of patients by scaling access to compounded drugs that have a proven track record of safety and effectiveness. With a team of pharmacist-founders who have built and operated retail compounding programs, Steel is well-positioned to identify both high-impact drug candidates and innovative delivery systems. Steel has selected a novel treatment for anal fissures as its product entry point. The company's Fizurex™ wipe utilizes a combination therapy that is commonly compounded by pharmacists and incorporates it into a single-use wipe. By bringing rigorous safety and efficacy testing, Current Good Manufacturing Practices (CGMP), and a patient-friendly format to this drug combination, Steel believes it can dramatically improve outcomes for patients.
